Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021

バイオシミラーの世界市場予測(~2021):製品別(組み換え非グリコシル化タンパク質(インスリン、rHGH、インターフェロン)、グリコシル化(mAb、EPO)、ペプチド(グルカゴン、カルシトニン)、製造別、用途別

◆タイトル:Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021
◆商品コード:MAM-BT-2160
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年1月5日
◆ページ数:154
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、バイオシミラーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品別分析、製造別分析、用途別分析、地域別分析、バイオシミラーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global biosimilars market is segmented on the basis of product, manufacturing type, and application. Factors such as rising incidence of various diseases, increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars are expected to drive the growth of this market. Emerging markets and new indications and patent expiry of biologic products has opened an array of opportunities for players in the biosimilars market. However, complexities in manufacturing and innovative strategies by biologic drug manufacturers are expected to restrain the growth of this market to a certain extent during the forecast period.
The biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3%.

On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is expected to account for the largest share of the market in 2016. Factors such as new product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are driving this market.

On the basis of manufacturing type, the biosimilars market is segmented into in-house manufacturing and contract manufacturing organizations. In 2016, the in-house manufacturing segment is expected to account for the largest share of the market. This growth can be attributed to the increasing demand for biosimilar products owing to the rising incidence of various diseases.

On the basis of application, the biosimilars market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The oncology segment is expected to grow at the highest CAGR during the forecast period.

Based on region, the biosimilars market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by Europe, followed by Asia, North America, and the Rest of the World (RoW). However, Asia is expected to witness the highest CAGR during the forecast period. This growth can be attributed to factors such as low per capita consumption, rapid growth in economies, rise in technological innovation, trade links, and the rise in medical tourism.

The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Biosimilars Market Definition
1.3 Biosimilars Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 18)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Biosimilars Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Biosimilars Market Breakdown & Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 26)
3.1 Introduction
3.2 Conclusion

4 Premium Insights (Page No. – 30)
4.1 Biosimilars: Market Overview
4.2 Geographic Analysis: Biosimilars Market, By Product
4.3 Biosimilars Market Size, By Application, 2016 vs 2021

5 Market Overview (Page No. – 33)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Incidences of Diseases
5.2.1.2 Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
5.2.1.3 Growing Pressure to Curtail Healthcare Expenditure
5.2.1.4 Rising Geriatric Population
5.2.1.5 Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
5.2.1.6 Increasing Government Support and Initiatives to Develop and Promote Biosimilars
5.2.2 Restraints
5.2.2.1 Complexities in Manufacturing and High Costs
5.2.2.2 Innovative Strategies By Biologic Drug Manufacturers
5.2.3 Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 New Indications and Patent Expiry of Biologic Products
5.2.4 Challenge
5.2.4.1 Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
5.3 Key Pipeline Products
5.4 Regulatory Outlook
5.4.1 North America
5.4.1.1 U.S.
5.4.1.2 Canada
5.4.2 Europe
5.4.3 Asia
5.4.3.1 China
5.4.3.2 India
5.4.3.3 Japan
5.4.3.4 South Korea
5.4.4 Rest of the World
5.4.4.1 Brazil
5.4.4.2 Mexico
5.4.4.3 Argentina
5.4.4.4 Saudi Arabia
5.5 Biosimilars Services Industry Insights
5.5.1 Introduction
5.5.2 Contract Manufacturing Organizations
5.5.3 Contract Research Organizations
5.5.4 Other Services (Nonclinical & Bioinformatics)

6 Biosimilars Market, By Type of Product (Page No. – 50)
6.1 Introduction
6.2 Recombinant Non-Glycosylated Proteins
6.2.1 Insulin
6.2.2 Recombinant Human Growth Hormone (RHGH)
6.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
6.2.4 Interferons
6.3 Recombinant Glycosylated Proteins
6.3.1 Erythropoietin (EPO)
6.3.2 Monoclonal Antibodies (MABS)
6.3.3 Follitropin
6.4 Recombinant Peptides
6.4.1 Glucagon
6.4.2 Calcitonin

7 Biosimilars Market, By Type of Manufacturing (Page No. – 68)
7.1 Introduction
7.2 In-House Manufacturing
7.3 Contract Manufacturing Organizations

8 Biosimilars Market, By Application (Page No. – 72)
8.1 Introduction
8.2 Oncology
8.3 Chronic and Autoimmune Diseases
8.4 Blood Disorders
8.5 Growth Hormone Deficiency
8.6 Infectious Diseases
8.7 Other Applications

9 Biosimilars Market, By Region (Page No. – 81)
9.1 Introduction
9.2 North America Biosimilars Market
9.2.1 U.S.
9.2.2 Canada
9.3 Europe Biosimilars Market
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Biosimilars Market
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest of Asia (RoA)
9.5 Rest of the World (RoW) Biosimilars Market

10 Competitive Landscape (Page No. – 113)
10.1 Overview
10.2 Biosimilars Market Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 Regulatory Approvals
10.3.2 Agreements, Collaborations, and Partnerships
10.3.3 Product Launches
10.3.4 Acquisitions
10.3.5 Expansions
10.3.6 Other Developments

11 Company Profiles (Page No. – 120)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 Introduction
11.2 Pfizer Inc.
11.3 Sandoz International GmbH (A Division of Novartis International AG)
11.4 Teva Pharmaceutical Industries Ltd.
11.5 F. Hoffmann-La Roche Ltd.
11.6 Amgen Inc.
11.7 Biocon Ltd.
11.8 Dr. Reddy’s Laboratories
11.9 Celltrion Inc.
11.10 Mylan Inc.
11.11 Samsung Bioepis

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. – 142)
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Available Customizations
12.6 Related Reports
12.7 Author Details

List of Tables (91 Tables)

Table 1 Biosimilars Market Summary
Table 2 Biosimilars Market: Major Collaborations (2012–2015)
Table 3 List of Key Biologics Under the Threat of Patent Expiry
Table 4 Biosimilars in Clinical Trials
Table 5 Status of Regulatory Pathway in North America
Table 6 Substitution Status in European Countries
Table 7 Status of Regulatory Pathway in Asia
Table 8 Status of Regulatory Pathway in the RoW
Table 9 Joint Ventures Between Cmos & Pharmaceutical Companies for Biosimilars
Table 10 Biosimilars Market Size, By Product Type, 2014–2021 (USD Million)
Table 11 Biosimilars Recombinant Non-Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 12 Biosimilars Recombinant Non-Glycosylated Proteins Market Size, By Region, 2014–2021 (USD Million)
Table 13 North America: Biosimilars Recombinant Non-Glycosylated Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 14 Europe: Biosimilars Recombinant Non-Glycosylated Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 15 Asia: Biosimilars Recombinant Non-Glycosylated Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 16 Biosimilars Insulin Market Size, By Region, 2014 –2021 (USD Million)
Table 17 Biosimilars Recombinant Human Growth Hormone Market Size, By Region, 2014–2021 (USD Million)
Table 18 List of Approved Biosimilars for Granulocyte Colony-Stimulating Factor Products From 2013 to 2016
Table 19 Biosimilars Granulocyte Colony-Stimulating Factor Market Size, By Region, 2014–2021 (USD Million)
Table 20 Biosimilars Interferons Market Size, By Region, 2014–2021 (USD Million)
Table 21 Biosimilars Recombinant Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 22 Biosimilars Recombinant Glycosylated Proteins Market Size, By Region, 2014–2021 (USD Million)
Table 23 North America: Biosimilars Recombinant Glycosylated Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 24 Europe: Biosimilars Recombinant Glycosylated Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 25 Asia: Biosimilars Recombinant Glycosylated Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 26 Biosimilars Erythropoietin Market Size, By Region, 2014–2021 (USD Million)
Table 27 Biosimilars Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Million)
Table 28 Biosimilars Follitropin Market Size, By Region, 2014–2021 (USD Million)
Table 29 Biosimilars Recombinant Peptides Market Size, By Type, 2014–2021 (USD Million)
Table 30 Biosimilars Recombinant Peptides Market Size, By Region, 2014–2021 (USD Million)
Table 31 North America: Biosimilars Recombinant Peptides Market Size, By Country, 2014–2021 (USD Million)
Table 32 Europe: Biosimilars Recombinant Peptides Market Size, By Country, 2014–2021 (USD Million)
Table 33 Asia: Biosimilars Recombinant Peptides Market Size, By Country, 2014–2021 (USD Million)
Table 34 Biosimilar Glucagon Market Size, By Region, 2014–2021 (USD Million)
Table 35 Biosimilar Calcitonin Market Size, By Region, 2014–2021 (USD Million)
Table 36 Biosimilars Market Size, By Manufacturing Type, 2014–2021 (USD Million)
Table 37 Biosimilars Market Size for In-House Manufactuirng, By Region, 2014–2021 (USD Million)
Table 38 Biosimilars Market Size for Contract Manufacturing Organizations, By Region, 2014–2021 (USD Million)
Table 39 Biosimilars Market Size, By Application, 2014–2021 (USD Million)
Table 40 Biosimilars Market Size for Oncology, By Region, 2014–2021 (USD Million)
Table 41 Biosimilars Market Size for Chronic and Autoimmune Diseases, By Region, 2014–2021 (USD Million)
Table 42 Biosimilars Market Size for Blood Disorders, By Region, 2014–2021 (USD Million)
Table 43 Biosimilars Market Size for Growth Hormone Deficiency, By Region, 2014–2021 (USD Million)
Table 44 Biosimilars Market Size for Infectious Diseases, By Region, 2014–2021 (USD Million)
Table 45 Biosimilars Market Size for Other Applications, By Region, 2014–2021 (USD Million)
Table 46 Biosimilars Market Size, By Region, 2014–2021 (USD Million)
Table 47 North America: Biosimilars Market Size, By Country, 2014–2021 (USD Million)
Table 48 North America: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 49 North America: Recombinant Non-Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 50 North America: Recombinant Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 51 North America: Recombinant Peptides Market Size, By Type, 2014–2021 (USD Million)
Table 52 North America: Biosimilars Market Size, By Application, 2014–2021 (USD Million)
Table 53 North America: Biosimilars Market Size, By Manufacturing Type, 2014–2021 (USD Million)
Table 54 U.S.: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 55 Canada: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 56 Europe: Biosimilars Market Size, By Country, 2014–2021 (USD Million)
Table 57 Europe: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 58 Europe: Recombinant Non-Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 59 Europe: Recombinant Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 60 Europe: Recombinant Peptides Market Size, By Type, 2014–2021 (USD Million)
Table 61 Europe: Biosimilars Market Size, By Application, 2014–2021 (USD Million)
Table 62 Europe: Biosimilars Market Size, By Manufacturing Type, 2014–2021 (USD Million)
Table 63 Germany: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 64 France: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 65 U.K.: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 66 Italy: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 67 Spain: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 68 RoE: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 69 Asia: Biosimilars Market Size, By Country, 2014–2021 (USD Million)
Table 70 Asia: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 71 Asia: Recombinant Non-Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 72 Asia: Recombinant Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 73 Asia: Recombinant Peptides Market Size, By Type, 2014–2021 (USD Million)
Table 74 Asia: Biosimilars Market Size, By Application, 2014–2021 (USD Million)
Table 75 Asia: Biosimilars Market Size, By Manufacturing Type, 2014–2021 (USD Million)
Table 76 China: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 77 India: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 78 Japan: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 79 South Korea: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 80 RoA: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 81 RoW: Biosimilars Market Size, By Product, 2014–2021 (USD Million)
Table 82 RoW: Recombinant Non-Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 83 RoW: Recombinant Glycosylated Proteins Market Size, By Type, 2014–2021 (USD Million)
Table 84 RoW: Recombinant Peptides Market Size, By Type, 2014–2021 (USD Million)
Table 85 RoW: Biosimilars Market Size, By Application, 2014–2021 (USD Million)
Table 86 Regulatory Approvals, 2013–2016
Table 87 Agreements, Collaborations, and Partnerships, 2013–2016
Table 88 Product Launches, 2013–2016
Table 89 Acquisitions, 2013–2016
Table 90 Expansions, 2013–2016
Table 91 Other Developments


List of Figures (42 Figures)

Figure 1 Research Methodology
Figure 2 Biosimilars Market: Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation Methodology
Figure 5 Biosimilars Market Size, By Product, 2016 vs 2021 (USD Billion)
Figure 6 Biosimilars Market Size, By Type of Manufacturing, 2016 vs 2021 (USD Billion)
Figure 7 Biosimilars Market Size, By Application, 2016 vs 2021 (USD Billion)
Figure 8 Geographical Snapshot of the Biosimilars Market
Figure 9 Biosimilars Market to Register A High, Double-Digit Growth Rate During the Forecast Period
Figure 10 Recombinant Non-Glycosylated Proteins Segment to Account for the Largest Market Share in 2016
Figure 11 Oncology Segment Will Continue to Dominate the Biosimilars Market in 2021
Figure 12 Asia to Register the Highest CAGR During the Forecast Period
Figure 13 Biosimilars Market: Drivers, Restraints, Opportunities, & Challenges
Figure 14 Global Incidences of Top Ten Cancer
Figure 15 Global Incidences of Diabeties
Figure 16 Biosimilars Market Size, By Product Type, 2014–2021
Figure 17 In-House Manufacturing Segment to Dominate the Biosimilars Market in 2016
Figure 18 Oncology to Dominate the Biosimilars Market in 2016
Figure 19 Global Cancer Incidence, By Region, 2012–2020
Figure 20 Europe to Dominate the Biosimilars Market in 2016
Figure 21 North America: Biosimilars Market Snapshot
Figure 22 Glucagon Segment to Hold the Largest Share of the North American Market
Figure 23 Europe: Biosimilars Market Snapshot
Figure 24 Erythropoietin Segment to Hold the Largest Share of the European Market
Figure 25 Asia: Biosimilars Market Snapshot
Figure 26 Recombinant Non-Glycosylated Proteins Segment to Hold Largest Share of the Asian Market
Figure 27 Oncology Segment to Hold Largest Share in the Asian Market in 2016
Figure 28 RoW: Biosimilars Market Snapshot
Figure 29 Granulocyte Colony-Stimulating Factor Segment to Hold Largest Share of the RoW Market in 2016
Figure 30 Key Developments Adopted By Market Players Between 2013 and 2016
Figure 31 Global Biosimilars Market Share, By Key Player, 2015
Figure 32 Battle for Market Share: Regulatory Approvals Was the Key Strategy Pursued By Market Players Between 2013 & 2016
Figure 33 Product Benchmarking for the Top 3 Players
Figure 34 Company Snapshot: Pfizer Inc.
Figure 35 Company Snapshot: Sandoz International GmbH
Figure 36 Company Snapshot: Teva Pharmaceutical Industries Ltd.
Figure 37 Company Snapshot: F. Hoffmann-La Roche Ltd.
Figure 38 Company Snapshot: Amgen Inc.
Figure 39 Company Snapshot: Biocon Ltd.
Figure 40 Company Snapshot: Dr. Reddy's Laboratories
Figure 41 Company Snapshot: Celltrion Inc.
Figure 42 Company Snapshot: Mylan Inc.

【レポートのキーワード】

バイオシミラー、バイオシミラー製品、組み換え非グリコシル化タンパク質、インスリン、rHGH、インターフェロン、グリコシル化、mAb、EPO、ペプチド、グルカゴン、カルシトニン、バイオシミラー製造、バイオシミラー用途

★調査レポート[バイオシミラーの世界市場予測(~2021):製品別(組み換え非グリコシル化タンパク質(インスリン、rHGH、インターフェロン)、グリコシル化(mAb、EPO)、ペプチド(グルカゴン、カルシトニン)、製造別、用途別] ( Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021 / MAM-BT-2160) 販売に関する免責事項
[バイオシミラーの世界市場予測(~2021):製品別(組み換え非グリコシル化タンパク質(インスリン、rHGH、インターフェロン)、グリコシル化(mAb、EPO)、ペプチド(グルカゴン、カルシトニン)、製造別、用途別] ( Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021 / MAM-BT-2160) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆